查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2022-2029 年全球神經退行性疾病市場
市場調查報告書
商品編碼
1143376

2022-2029 年全球神經退行性疾病市場

Global Neurodegenerative Disease Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

在預測期間（2022-2029 年），神經退行性疾病市場規模預計將以 7.4% 的複合年增長率增長。

阿爾茨海默病、帕金森病和亨廷頓病等神經退行性疾病會影響人腦中的神經元，使其無法自我更新。因此，神經元死亡意味著永久性喪失，而這種喪失是無法替代的。

市場動態

神經退行性疾病市場的增長包括神經系統疾病患病率的上升、社會意識的提高、老年人口的增加以及神經退行性疾病治療的強大產品線。

預計神經退行性疾病患病率的上升將推動市場增長。

隨著年齡的增長，我們更有可能患上阿爾茨海默病、帕金森病和譫妄等神經退行性疾病。在預測期內，不斷增長的老年人口將推動全球神經退行性疾病市場。例如，據 NIH 稱，譫妄影響超過 14% 至 56% 的住院老年患者，每年有超過 1250 萬 65 歲及以上的患者患有譫妄。例如，根據美國經濟和社會事務局的數據，2020 年 65 歲及以上的人口數量約為 2.72 億，預計到 2050 年將達到 15 億。大約 9.3% 的人口是老年人，預計到 2050 年將增長到 16% 以上。

此外，45 歲以上的人中，每 10 人中就有 1 人患有主觀認知能力下降，據世界衛生組織統計，全球 41% 的老年人口無法進行日常活動。世界老年人口中約有5500萬人患有癡呆症，據說每年有1000萬人患癡呆症。此外，據阿爾茨海默病國際組織稱，到 2020 年，全球癡呆症患者人數將超過 5500 萬，預計 2030 年和 2050 年將達到 7800 萬和 1.39 億。目前，人們每年因癡呆症造成的損失超過 1.3 萬億美元，預計到 2030 年將達到 2.8 萬億美元。此外，根據國際帕金森病與運動障礙協會的數據，預計2020年全球將有約940萬人患上帕金森病。

嚴格的監管指南和專利到期預計將阻礙全球神經退行性疾病市場的增長。

然而，藥物開發和神經退行性疾病治療產品專利到期的嚴格監管指南是預計阻礙全球神經退行性疾病市場增長的主要因素。

行業分析

《全球神經退行性疾病市場報告》根據波特五力、創新、新產品發布、定價分析和管道分析等各種行業因素對市場進行了深入分析。

細分分析

預計帕金森病細分市場將在整個預測期內（2022-2029 年）主導神經退行性疾病市場。

預計帕金森病在預測期內將以最高的複合年增長率增長，原因是患病率上升以及對該病治療方法的研發增加。帕金森病是繼阿爾茨海默病之後第二常見的與年齡相關的神經退行性疾病。據估計，全世界約有 1000 萬人患有帕金森病。患病率從生命第四年的每 100,000 人 41 人到 80 歲以上的每 100,000 人超過 1,900 人不等。根據帕金森病基金會的數據，全世界約有 1000 萬人被診斷出患有帕金森病。帕金森病的風險隨著年齡的增長而增加。根據帕金森病基金會的數據，帕金森病患者每年平均花費 2,500 美元用於藥物治療，每人花費近 100,000 美元用於手術干預。目前帕金森病的治療方法包括左旋多巴和多巴胺激動劑，它們可以減少與該疾病相關的早期運動症狀。然而，隨著疾病的進展和神經細胞的退化，這些治療最終對症狀變得不那麼有效。此外，2022 年 1 月 7 日，Alembic Pharmaceuticals 獲得了美國衛生當局的最終批准，用於帕金森病患者的通用 Entacapone 片劑。

區域分析

北美地區佔全球神經退行性疾病市場的最大市場份額。

由於該地區阿爾茨海默病的發病率不斷上升，北美在全球神經退行性疾病市場中佔據主導地位，在 2021 年佔據最大的市場份額。根據阿爾茨海默病協會的數據，到 2022 年，65 歲以上的美國人將有 650 萬患有阿爾茨海默病。到 2050 年，65 歲及以上患有阿爾茨海默病的人數可能會上升到 1270 萬。還有數千名未被發現的患者。阿爾茨海默病是 2020 年和 2021 年美國第七大死亡原因。隨著美國的老齡化，患有神經退行性疾病的人數繼續增加。據帕金森基金會稱，每年估計有 60,000 名美國人被診斷出患有 PD。到 2022 年底，阿爾茨海默病和其他癡呆症的成本可能達到 3210 億美元，到 2050 年將接近 1 萬億美元。

競爭格局

神經退行性疾病市場包括 AbbVie Inc.、Amneal Pharmaceuticals Inc.、Boehringer Ingelheim International GmbH、F. Hoffmann-La Roche Ltd.、GlaxoSmithKline PLC、Merck&Co.Inc.、Pfizer Inc.、Teva Pharmaceutical、UCB SA、Novartis和別的。領先企業正在採取各種增長戰略，例如產品發布、併購、合作夥伴關係和合作，為全球神經退行性疾病市場的增長做出貢獻。例如，2022 年 8 月 16 日，GlaxoSmithKline收購了 Affinivax, Inc.。 2022年5月，Pfizer同意收購Biohaven。

Novartis

概述

Novartis是一家全球領先的製藥公司，總部位於瑞士巴塞爾和美國馬薩諸塞州劍橋市。Novartis於 1996 年由 Ciba-Geigy 和 Sandoz 合併而成。

產品組合

Novartis的神經退行性疾病產品組合包括用於治療帕金森病的 Nourianz（伊曲茶鹼）片劑和用於治療輕度至中度阿爾茨海默病的 EXELON(R) PATCH（卡巴拉汀透皮系統）。

全球神經退行性疾病市場報告提供對 40 多個 市場數據表、45 多個圖表和 200 頁（大約）的訪問。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 神經退行性疾病增加
      • 對研發的貢獻
    • 約束因素
      • 嚴格的開發規定
      • 專利已過期
    • 商機
    • 影響分析

第五章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章適應症

  • 帕金森病
  • 肌萎縮側索硬化症
  • 阿爾茨海默氏症
  • 亨廷頓氏病
  • 其他

第 8 章按藥物類型

  • N-甲基-D-天冬氨酸受體製劑
  • 選擇性血清素再攝取抑製劑
  • 多巴胺抑製劑
  • 其他

第 9 章，最終用戶

  • 醫院和診所
  • 其他

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準

第 12 章公司簡介

  • Novartis
    • 公司簡介
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • AbbVie Inc.
  • Amneal Pharmaceuticals Inc.
  • Boehringer Ingelheim International GmbH
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Teva Pharmaceutical
  • UCB SA

第 13 章數據M

簡介目錄
Product Code: DMPH2090

Market Overview

Neurodegenerative Disease Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 7.4% during the forecast period (2022-2029).

Neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's, among others disorders, affect the neurons in the human brain, leading to the inability of neurons to reproduce themselves. Thus, the death of neurons indicates permanent loss, which cannot be replaced.

Market Dynamics

The growth of the neurodegenerative disease market includes the rising prevalence of neurological disorders, increasing public awareness, a growing geriatric population and a strong product pipeline for neurodegenerative disease treatment.

The rising prevalence of neurodegenerative diseases is expected to drive market growth.

With the growing age, there is a high susceptibility to developing one or other neurodegenerative diseases such as Alzheimer's, Parkinson's, Delirium, Etc. The rising geriatric population drives the global neurodegenerative disease market during the forecast period. For instance, according to the NIH, delirium affects over 14-56% of hospitalized geriatric patients; over 12.5 million patients aged 65 or over yearly suffer delirium. For instance, the Department of Economics and Social Affairs United States data shows that in 2020 the number of people aged 65 and over was around 272 million, which is predicted to reach 1.5 billion by 2050. The geriatric population is around 9.3 % and is predicted to be over 16% until 2050.

Moreover, 1 in 10 people aged 45 and above suffer from Subjective Cognitive Decline, which has led to giving daily activities in 41% of the global geriatric population as per the WHO. Also, nearly 55 million global geriatric population have dementia, with 10 million cases yearly. Furthermore, according to Alzheimer's Disease International, there were over 55 million people worldwide living with dementia in 2020, and it is estimated to reach 78 million in 2030 and 139 million in 2050; the annual global cost of dementia is now above US$ 1.3 trillion and is expected to rise to US$ 2.8 trillion by 2030. In addition, International Parkinson and Movement Disorder Society data indicates that globally around 9.4 million people with Parkinson's Disease in 2020.

The stringent regulatory guidelines and patent expiry are expected to hinder global neurodegenerative disease market growth.

However, the stringent regulatory guidelines for drug development and the expiry of neurodegenerative disease treatment product patents are the major factors that are anticipated to hamper the global neurodegenerative diseases market growth.

Industry Analysis

The global neurodegenerative disease market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, innovations, new product launches, pricing analysis, and pipeline analysis.

Segment Analysis

The Parkinson's disease segment is expected to dominate the neurodegenerative disease market throughout the forecast period (2022-2029).

Parkinson's disease is expected to grow at the highest CAGR during the forecast period, owing to the rising prevalence of Parkinson's disease and increasing R&D for the treatment of this disease. Parkinson's disease is the second most common age-related neurodegenerative disorder after Alzheimer's. An estimated 10 million people worldwide have Parkinson's disease. The prevalence of the disease ranges from 41 people per 100,000 in the fourth decade of life to more than 1,900 people per 100,000 among those who are 80 and older. According to the Parkinson's Disease Foundation, approximately 10 million people globally are diagnosed with Parkinson's disease. The risk of Parkinson's disease increases with age. According to the Parkinson's Disease Foundation, the medication cost for a patient with the disease is, on average, USD 2,500 a year, and therapeutic surgery costs nearly USD 100,000 per person. The current treatments for Parkinson's, include levodopa and dopamine agonists, which can help manage early motor symptoms associated with the disease. However, as the disease progresses and neurons degenerate, these therapies ultimately become less effective at treating the symptoms. Furthermore, on January 7, 2022, Alembic Pharmaceuticals received final approval from the US health regulator for its generic Entacapone tablets indicated for patients with Parkinson's disease.

Geographical Analysis

The North American region holds the largest market share of the global neurodegenerative disease market.

North America is dominating the global neurodegenerative disease market, accounting for the largest market share in 2021, owing to the increasing incidence of Alzheimer's disease in this region. According to Alzheimer's Association, in 2022, 6.5 million Americans age 65 and older are living with Alzheimer's. By 2050, the number of people aged 65 and older with Alzheimer's may grow to 12.7 million. Also, there are thousands of patients who go undetected. Alzheimer's is the seventh-leading cause of death in the United States in 2020 and 2021. As the US population ages, the number of people living with neurodegenerative diseases continues to grow. An estimated 60,000 Americans are diagnosed with PD each year, as per Parkinson's Foundation. In addition, by the end of 2022, Alzheimer's and other dementias will cost the nation $321 billion, and by 2050, these costs could reach nearly $1 trillion.

Competitive Landscape

The neurodegenerative disease market is highly competitive with the presence of a large number of players, including AbbVie Inc., Amneal Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Merck & Co. Inc., Pfizer Inc., Teva Pharmaceutical, UCB SA, Novartis, among others. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations contributing to the growth of the neurodegenerative disease market globally. For instance, on 16 August 2022, GSK acquired Affinivax, Inc. Also, in May 2022, Pfizer agreed to acquire Biohaven.

Novartis AG

Overview:

Novartis AG is a leading global pharmaceutical manufacturing company based in Basel, Switzerland and Cambridge, Massachusetts, United States. Novartis AG was founded in 1996 through the merger of Ciba-Geigy and Sandoz.

Product Portfolio:

Novartis AG's product portfolio for the neurodegenerative disease has Nourianz (istradefylline) tablets for Parkinson's and EXELON® PATCH (rivastigmine transdermal system) for mild to moderate Alzheimer's.

The global neurodegenerative disease market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Prevalence of Neurodegenerative Diseases
      • 4.1.1.2. Research and Development
    • 4.1.2. Restraints
      • 4.1.2.1. The Stringent Developmental Regulations
      • 4.1.2.2. Patent Expiry
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Indication Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type Segment
    • 7.1.2. Market Attractiveness Index, By Indication Type Segment
  • 7.2. Parkinson's Disease
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Amyotrophic Lateral Sclerosis
  • 7.4. Alzheimer's Disease
  • 7.5. Huntington Disease
  • 7.6. Others

8. By Drug Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type Segment
    • 8.1.2. Market Attractiveness Index, By Drug Type Segment
  • 8.2. N-methyl-D-aspartate Receptor
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Selective Serotonin Reuptake Inhibitor
  • 8.4. Dopamine Inhibitors
  • 8.5. Others

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User Segment
  • 9.2. Hospitals and Clinics
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Other

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Company Profiles

  • 12.1. Novartis
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. AbbVie Inc.
  • 12.3. Amneal Pharmaceuticals Inc.
  • 12.4. Boehringer Ingelheim International GmbH
  • 12.5. F. Hoffmann-La Roche Ltd.
  • 12.6. GlaxoSmithKline PLC
  • 12.7. Merck & Co. Inc.
  • 12.8. Pfizer Inc.
  • 12.9. Teva Pharmaceutical
  • 12.10. UCB SA

LIST NOT EXHAUSTIVE

13. DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us